Regulation of mTOR by polycystin-1: Is polycystic kidney disease a case of futile repair?

Cell Cycle

Volumn 5, Issue 21, 2006, Pages 2425-2429

  Weimbs, Thomas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Kidney injury and repair; mTOR; Polycystic kidney disease; Polycystin; Rapamycin; Tuberin; Tuberous sclerosis complex

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; POLYCYSTIN 1; POLYCYSTIN 2; RAPAMYCIN; TUBERIN;

AUTOSOMAL DOMINANT DISORDER; COMPLEX FORMATION; HUMAN; KIDNEY CYST; KIDNEY INJURY; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; MECHANOTRANSDUCTION; NONHUMAN; REVIEW; TREATMENT RESPONSE;

RODENTIA;

EID: 33751208607     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.21.3408     Document Type: Review

References (46)

1. Harris PC, Torres VE. Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy. Curr Opin Nephrol Hypertens 2006; 15:456-63.
2. Sutters M, Germino GG. Autosomal dominant polycystic kidney disease: Molecular genetics and pathophysiology. J Lab Clin Med 2003; 141:91-101.
3. Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002; 13:2384-98.
4. Ong AC, Harris PC. Molecular pathogenesis of ADPKD: The polycystin complex gets complex. Kidney Int 2005; 67:1234-47.
5. Giamarchi A, Padilla F, Coste B, Raoux M, Crest M, Honore E, Delmas P. The versatile nature of the calcium-permeable cation channel TRPP2. EMBO Rep 2006; 7:787-93.
6. Praetorius HA, Spring KR. Bending the MDCK cell primary cilium increases intracellular calcium. J Membr Biol 2001; 184:71-9.
7. Praetorius HA, Spring KR. The renal cell primary cilium functions as a flow sensor. Curr Opin Nephrol Hypertens 2003; 12:517-20.
8. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, Elia AE, Lu W, Brown EM, Quinn SJ, Ingber DE, Zhou J. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003; 33:129-37.
9. Low SH, Vasanth S, Larson CH, Mukherjee S, Sharma N, Kinter MT, Kane ME, Obara T, Weimbs T. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev Cell 2006; 10:57-69.
10. Zhang Q, Taulman PD, Yoder BK. Cystic kidney diseases: All roads lead to the cilium. Physiology (Bethesda) 2004; 19:225-30.
11. Pazour GJ. Intraflagellar transport and cilia-dependent renal disease: The ciliary hypothesis of polycystic kidney disease. J Am Soc Nephrol 2004; 15:2528-36.
12. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T. From the Cover: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103:5466-71.
13. Henske EP. Tuberous sclerosis and the kidney: From mesenchyme to epithelium, and beyond. Pediatr Nephrol 2005; 20:854-7.
14. Astrinidis A, Henske EP. Tuberous sclerosis complex: Linking growth and energy signaling pathways with human disease. Oncogene 2005; 24:7475-81.
15. Kwiatkowski DJ, Manning BD. Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 2005; 14:R251-8.
16. Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, Everitt J, Xu H, Kiguchi K, Landes G, Harris P, Walker C. Tuberin-dependent membrane localization of polycystin-1: A functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell 2001; 7:823-32.
17. Sandford R, Sgotto B, Burn T, Brenner S. The tuberin (TSC2), autosomal dominant polycystic kidney disease (PKD1), and somatostatin type V receptor (SSTR5) genes form a synteny group in the Fugu genome. Genomics 1996; 38:84-6.
18. Sampson JR, Maheshwar MM, Aspinwall R, Thompson P, Cheadle JP, Ravine D, Roy S, Haan E, Bernstein J, Harris PC. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet 1997; 61:843-51.
19. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37:19-24.
20. Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: Filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 2004; 29:32-8.
21. Pan D, Dong J, Zhang Y, Gao X. Tuberous sclerosis complex: From Drosophila to human disease. Trends Cell Biol 2004; 14:78-85.
22. Law BK. Rapamycin: An anti-cancer immunosuppressant? Crit Rev Oncol Hematol 2005; 56:47-60.
23. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16:46-51.
24. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21:598-604.
25. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003; 17:1829-34.
26. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003; 13:1259-68.
27. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol 2005; 15:702-13.
28. Sweeney Jr WE, Avner ED. Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD). Cell Tissue Res 2006; In press.
29. Torres VE, Sweeney Jr WE, Wang X, Qian Q, Harris PC, Frost P, Avner ED. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int 2003; 64:1573-9.
30. Torres VE, Sweeney Jr WE, Wang X, Qian Q, Harris PC, Frost P, Avner ED. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Kidney Int 2004; 66:1766-73.
31. Omori S, Hida M, Fujita H, Takahashi H, Tanimura S, Kohno M, Awazu M. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 2006; 17:1604-14.
32. Alexander LD, Ding Y, Alagarsamy S, Cui XL, Douglas JG. Arachidonic acid induces ERK activation via Src SH2 domain association with the epidermal growth factor receptor. Kidney Int 2006; 69:1823-32.
33. Tanner GA, McQuillan PF, Maxwell MR, Keck JK, McAteer JA. An in vitro test of the cell stretch-proliferation hypothesis of renal cyst enlargement. J Am Soc Nephrol 1995; 6:1230-41.
34. Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS, Valeri R, Levine JS. Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281:F693-706.
35. Vasquez EM. Sirolimus: A new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000; 57:437-48, (quiz 49-51).
36. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006; 17:1503-20.
37. Bonventre JV. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 2003; 14:S55-61.
38. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15:1-12.
39. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006; 69:2029-36.
40. Chen JK, Chen J, Neilson EG, Harris RC. Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 2005; 16:1384-91.
41. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ, Lieberthal W. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16:2063-72.
42. Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 2006; 340:296-301.
43. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17:1395-404.
44. Chauvet V, Tian X, Husson H, Grimm DH, Wang T, Hieseberger T, Igarashi P, Bennett AM, Ibraghimov-Beskrovnaya O, Somlo S, Caplan MJ. Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest 2004; 114:1433-43.
45. Walz G. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): Is there light at the end of the tunnel? Nephrol Dial Transplant 2006; 21:1752-7.
46. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Canccer Res 2002; 62:5645-50.